PCC Rokit (PCR) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
10 Nov, 2026Executive summary
9M 2026 revenue rose 3.1% to PLN 1,415.2m, EBITDA increased 21.4% to PLN 241.1m and net income rose 126.5% to PLN 92.4m.
Polyurethanes led earnings growth, while chlorinated derivatives weakened; diversification supported results amid weak demand and macroeconomic uncertainty.
The outlook remained cautious, with limited signs of industrial demand recovery and continued geopolitical and economic uncertainty.
Financial highlights
9M gross profit reached PLN 264.8m, up 11.4%; gross margin increased to 18.7% from 17.3%.
9M EBIT rose 55.8% to PLN 127.7m; EBITDA was PLN 241.1m and net income PLN 92.4m.
Q3 revenue was PLN 470.7m versus PLN 414.5m YoY, while EBITDA fell to PLN 62.2m from PLN 80.3m and net income to PLN 13.1m from PLN 32.6m.
9M operating cash flow was PLN 208.3m; investing and financing cash flows were -PLN 81.0m and -PLN 97.2m, respectively.
EPS was PLN 4.56 versus PLN 2.06; net cash increased PLN 30.1m in 9M.
Outlook and guidance
No 2026 financial forecast was issued; operating cash flow was expected to fund operations, investment spending and debt service, subject to market conditions.
Q4 polyurethane prospects remained cautious, with no clear durable European demand recovery; oversupply, imports and high costs continued to pressure prices and margins.
Possible provisional EU anti-dumping duties on selected Chinese polyether polyols were not expected before Q1 2027; impact remained limited through Q3.
The Brzeg Dolny plant project is planned for completion by end-2028, with estimated capex of PLN 842m ±15%; staging remains possible as market conditions change.
Latest events from PCC Rokit
- Net profit and EBITDA soared in 1H2026, with Polyurethanes leading growth amid market risks.PCR
Q2 2026 - Revenue and EBITDA fell sharply, with only Polyurethanes showing margin gains amid tough conditions.PCR
Q1 2026 - Net profit rose 5.6% to 40.8 million PLN despite a 6% revenue drop, aided by energy compensation.PCR
Q3 2025 - 2025 saw lower revenue and profit but higher sales volume and continued investment.PCR
Q4 2025 - H1 2025 saw sharp declines in revenue, EBITDA, and profit, but liquidity remained resilient.PCR
Q2 2025 - EBITDA and net profit fell sharply in 1-3Q 2024, driven by weak Chlorine Derivatives.PCR
Q3 2024 - Revenue and profit dropped, but liquidity and investment activity remained strong.PCR
Q2 2024 - EBITDA fell 28% and net profit 47% year-over-year, with chlorinated derivatives underperforming.PCR
Q4 2024 - EBITDA and net profit fell sharply in Q1 2025, despite higher revenue and ongoing investments.PCR
Q1 2025